FDA Import Refusal BNI-0093509-6/131/1 — Pointlink Investment Limited
The FDA refused shipment BNI-0093509-6/131/1 from Pointlink Investment Limited (Nigeria) on Dec 22, 2020. The refused product falls under Drugs and Biologics — ASPIRIN (ANALGESIC). Cited charges: 118,3280 This firm has 1 other import refusal on record.
Refusal details
- Date
- Dec 22, 2020
- Country
- Nigeria
- Product Category
- Drugs and Biologics
- Product Code
- 60LDR05 ASPIRIN (ANALGESIC)
- Charges
- 118,3280